Researchers at the Riken Center for Advanced Intelligence Project in Japan developed artificial intelligence (AI) technology that found previously unknown features related to prostate cancer occurrence in unannotated pathology images.
Israeli startup Zebra Medical Vision Ltd. has partnered with Johnson & Johnson’s Depuy Synthes to develop artificial intelligence (AI)-based algorithms to reduce the costs and radiation risks associated with imaging to prepare for orthopedic surgery.
Drug diversion in hospitals is a serious concern, facilitated in part by inadequate security controls that allow unauthorized staff to access the pharmacy stock. To help thwart this problem and improve medication management, Taipei, Taiwan-based Cyberlink Corp. and Imedtac Co. Ltd. are teaming up to bring facial recognition technology to the hospital medicine cabinet.
Drug diversion in hospitals is a serious concern, facilitated in part by inadequate security controls that allow unauthorized staff to access the pharmacy stock. To help thwart this problem and improve medication management, Taipei, Taiwan-based Cyberlink Corp. and Imedtac Co. Ltd. are teaming up to bring facial recognition technology to the hospital medicine cabinet.
HONG KONG – Aiming to attract more active innovation to its medical device industry, South Korea updated some of its industry regulations through 2019. The ultimate goal was to make it easier for advanced medical technologies that use artificial intelligence (AI), robotics and 3D printing that have yet to penetrate the market due to inefficient approval processes.
Health care-associated infections (HAI) pose a constant challenge for hospitals and health systems, resulting in increased morbidity and mortality and billions in costs each year. According to the Centers for Disease Control and Prevention, about 1 in 31 patients has at least one HAI at any given time. In 2016, the U.S. Department of Health and Human Services set a 2020 goal of reducing HAIs by 50% below a 2015 baseline. To that end, Biotia Inc. plans to launch an artificial intelligence (AI)-enabled test to detect harmful bugs and antimicrobial resistance (AMR) early in the new year.
HONG KONG – Pentax Medical Co., of Tokyo, has gained CE marking for its artificial intelligence-based polyp detector Discovery. The detector assists endoscopists in finding potential polyps during a colorectal examination. The software has been trained using more than 120,000 files from about 300 clinical cases.
Heart failure is a leading cause of disability and death in the U.S., but many cases are diagnosed late due to limited access to echocardiography, the primary method of detecting the condition. To address that need, the U.S. FDA has granted breakthrough device designation to Eko Devices Inc., of Berkeley, Calif., for an electrocardiogram (ECG)-based algorithm that could serve as an easily accessible screening tool for heart failure during routine physical exams.
PARIS – A team of medical researchers and engineers from the Gustave Roussy Institute, in Villejuif, France, and Paris-Sud University recently developed an artificial intelligence system called Resolved2, designed to assess prospective cancer drugs. As Loïc Verlingue, lead cancer specialist on the data science team at the Gustave Roussy Institute, explained to BioWorld MedTech, “this AI is intended to predict efficiently whether a cancer treatment molecule will achieve authorization or not within six years of pharmacological data and phase I clinical trials.”
Irving, Texas-based Caris Life Sciences Inc. has launched an AI-based genomic profiling test to better characterize cases of cancer of unknown primary origin (CUP) and atypical cases and offer appropriate treatment options. Known as the MI GPS (Genomic Profiling Similarity) Score, the analysis is based on an AI analysis of a 592-gene panel of all the clinically relevant genetic biomarkers for cancer.